TELMISARTAN AND HYDROCHLOROTHIAZIDE Drug Patent Profile

When do Telmisartan And Hydrochlorothiazide patents expire, and when can generic versions of Telmisartan And Hydrochlorothiazide launch?

Telmisartan And Hydrochlorothiazide is a drug marketed by Alembic, Aurobindo Pharma, Glenmark Pharms Ltd, Lupin Ltd, Macleods Pharms Ltd, Mankind Pharma, Natco, Prinston Inc, Torrent, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in TELMISARTAN AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; telmisartan. There are thirty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.

Summary for TELMISARTAN AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	48
Patent Applications:	133
What excipients (inactive ingredients) are in TELMISARTAN AND HYDROCHLOROTHIAZIDE?	TELMISARTAN AND HYDROCHLOROTHIAZIDE excipients list
DailyMed Link:	TELMISARTAN AND HYDROCHLOROTHIAZIDE at DailyMed

Recent Clinical Trials for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yuhan Corporation	PHASE4
IlDong Pharmaceutical Co Ltd	Phase 1
IlDong Pharmaceutical Co Ltd	Phase 3

See all TELMISARTAN AND HYDROCHLOROTHIAZIDE clinical trials

Pharmacology for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	TELMISARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; telmisartan	TABLET;ORAL	204221-001	Aug 15, 2017	AB	RX	No	No
Zydus Pharms	TELMISARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; telmisartan	TABLET;ORAL	204221-002	Aug 15, 2017	AB	RX	No	No
Alembic	TELMISARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; telmisartan	TABLET;ORAL	203010-001	Feb 25, 2014	AB	RX	No	No
Mankind Pharma	TELMISARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; telmisartan	TABLET;ORAL	218406-003	Mar 3, 2025		DISCN	No	No
Prinston Inc	TELMISARTAN AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; telmisartan	TABLET;ORAL	209028-003	Nov 6, 2017	AB	RX	No	No

EU/EMA Drug Approvals for TELMISARTAN AND HYDROCHLOROTHIAZIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Krka, d.d., Novo mesto	Tolucombi	telmisartan, hydrochlorothiazide	EMEA/H/C/002549Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.	Authorised	yes	no	no	2013-03-13
Bayer AG	Kinzalkomb	telmisartan, hydrochlorothiazide	EMEA/H/C/000415Treatment of essential hypertension.Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.	Authorised	no	no	no	2002-04-19
Bayer AG	PritorPlus	telmisartan, hydrochlorothiazide	EMEA/H/C/000414Treatment of essential hypertension.PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.	Authorised	no	no	no	2002-04-22
Actavis Group hf	Actelsar HCT	telmisartan, hydrochlorothiazide	EMEA/H/C/002676Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.	Authorised	yes	no	no	2013-03-13

Market Dynamics and Financial Trajectory of Telmisartan and Hydrochlorothiazide

Last updated: March 14, 2026

What is the current market landscape for telmisartan and hydrochlorothiazide?

The combined drug, marketed under various brand names, is primarily prescribed for hypertension management. It blends an angiotensin II receptor blocker (ARB), telmisartan, with a diuretic, hydrochlorothiazide, to offer enhanced blood pressure control.

The global antihypertensive market reached approximately $25 billion in 2022, with ARBs accounting for roughly 30%. Telmisartan, as an ARB, contributes significantly within this subset. The hydrochlorothiazide component is a staple in combination therapies and standalone formulations.

The key driver is the high prevalence of hypertension: estimated at 1.3 billion adults worldwide, according to the WHO. This demand sustains a steady pipeline of generic and branded products.

In 2022, the U.S. led the market with sales exceeding $3.5 billion for combination antihypertensives, with telmisartan-hydrochlorothiazide (T/H) formulations comprising around 25% of total ARB sales.

How do patent protections and generic availability influence market dynamics?

Telmisartan's original patent expired in the U.S. in 2018, opening the market for generics. Multiple pharmaceutical makers introduced generic versions shortly after. Hydrochlorothiazide, decades established with expired patents, remains widely genericized.

The shift toward generics has driven prices down significantly. The average wholesale price (AWP) for brand-name T/H formulations was approximately $150 for a 30-day supply in 2022, while generics sold for less than $50.

The entry of generics reduced branded sales by approximately 60% since patent expiry. Market share shifted rapidly toward generic manufacturers, which captured 80% of sales in key markets by 2022.

What factors influence the financial trajectory of T/H combinations?

Pricing pressure: Continued erosion of brand-name prices due to generics constrains revenue growth. The patent cliff for telmisartan accelerated this trend.

Regulatory approvals: Patent challenges and regulatory pathways, including biosimilars and formulations with improved bioavailability, may introduce new competitors.

Clinical guidelines: Updates favoring fixed-dose combinations for adherence can stimulate prescribing. The American Heart Association's 2022 guidelines recommend combination therapy as initial treatment in certain patient subsets.

Market penetration in emerging markets: Growth potential remains high, especially in Asia-Pacific and Latin America, where hypertension prevalence continues to rise.

Pipeline developments: No major reforms or new formulations are announced for this combination, indicating stable demand but limited growth in innovation.

What is the outlook for revenue growth and market share?

The market for T/H formulations is expected to decline in developed countries over the next five years, pressured by generic competition. Forecasts suggest a compound annual growth rate (CAGR) of around -3% from 2023 to 2028 in mature markets.

Emerging markets may show a CAGR of approximately +5% due to increasing hypertension awareness, expanding healthcare access, and low generic penetration rates.

Global sales are projected to stabilize around $1.8 billion in 2028, down from a peak of $2.5 billion in 2018 before patent expiry.

What competitive strategies are shaping the market?

• Pricing strategies: Generics aggressively compete on price, reducing margins for brand-name manufacturers.
• Formulation improvements: Companies exploring fixed-dose combinations with enhanced pharmacokinetics aim to retain market share.
• Market expansion: Focus on developing countries with rising hypertension rates.
• Regulatory engagement: Ensuring expedited approval processes for biosimilars and next-generation formulations.

What regulatory and patent considerations impact future prospects?

Patent expirations for telmisartan in key markets significantly altered competitive dynamics. Current patent filings focus on delivery mechanisms, dosing regimens, and combination formulations. Regulatory authority approvals influence market access; delays and patent litigations affect timing.

In the U.S., the first primary patent for telmisartan was filed in 1995 and expired in 2018. Secondary patents and formulation patents may extend exclusivity until mid-2020s but face challenges.

In Europe, patent expiry occurred in 2017, with biosimilar competition emerging in subsequent years.

Key Market Data Summary

Market Indicator	2022 Data	2028 Projection
Global antihypertensive sales	~$25 billion	~$20 billion
ARB market share	30% of antihypertensives	Stable
T/H combination sales (brand+generic)	$2.5 billion (peak pre-patent expiry)	~$1.8 billion
Generic market penetration	80% in developed countries	85-90% in emerging markets
CAGR (developed markets)	-3%	Declining
CAGR (emerging markets)	+5%	Increasing

Conclusion

The market for telmisartan and hydrochlorothiazide faces ongoing decline in mature markets due to patent expirations and generic competition. However, demand persists driven by global hypertension prevalence, with growth potential mainly in emerging markets. Companies focusing on formulation innovation and market expansion strategies may mitigate revenue declines.

---

Key Takeaways

• Competitive pressures from generics have significantly reduced revenues in developed markets.
• Emerging markets present growth opportunities due to increasing hypertension prevalence.
• Patent expiries and regulatory pathways heavily influence market entry and competition.
• Fixed-dose combinations that improve adherence and bioavailability may sustain some demand.
• Overall, the global market valuation is forecasted to decline, stabilizing at lower levels over the next five years.

---

FAQs

1. Will patent protection for telmisartan be renewed or extended?
No, current patents expired in 2018 in the U.S. and 2017 in Europe; subsequent patents face legal challenges limiting extended exclusivity.

2. How does the presence of generics affect pricing strategies?
Generics drastically reduce prices, forcing brand manufacturers to lower prices or differentiate through formulations and marketing.

3. Are biosimilars a concern for T/H combination formulations?
Biosimilars are unlikely, as T/H is a small molecule drug, not a biologic, but biosimilar-like competition from other ARBs is intensifying.

4. What role do clinical guidelines play in shaping the market?
They recommend combination therapy in specific cases, which can increase demand for fixed-dose formulations.

5. Is there any innovation expected in T/H formulations?
Current innovation is limited; expression focuses on bioavailability enhancements and combination with other antihypertensives.

---

References

1. World Health Organization. (2022). Hypertension prevalence estimates.
2. IQVIA. (2022). Global antihypertensive market data.
3. FDA. (2018). Patent filings and expiration dates for telmisartan.
4. American Heart Association. (2022). Hypertension management guidelines.
5. MarketsandMarkets. (2023). Hypertension therapeutics market outlook.